Colliers Securities Initiates Coverage on Legend Biotech (NASDAQ:LTRN)

Share on StockTwits

Colliers Securities started coverage on shares of Legend Biotech (NASDAQ:LTRN) in a report published on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

LTRN opened at $12.32 on Tuesday. Legend Biotech has a 1-year low of $11.51 and a 1-year high of $15.44.

About Legend Biotech

Lantern Pharma Inc, a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer.

Further Reading: How is an ETF different from a mutual fund?

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.